MRI INTERVENTIONS CLEARPOINT@ NEURO NAVIGATION SYSTEM UTILIZED IN MINNESOTA University of Minnesota Fairview Offers Real-Time MRI Guided Minimally Invasive Brain Surgery

IRVINE, CA., December 18, 2017 - MRI Interventions, Inc. (OTCQB: MRIC), a commercial stage medical device company focused on Magnetic Resonance Imaging (IVIRI)-Guided Neurosurgical procedures, announced today the first brain tumor surgery performed using the ClearPoint surgical navigation device in Minnesota at the University of Minnesota Medical Center.

"When surgeries are perfonned in a conventional operating room, large skin incisions and removal of a significant portion of the skull are often required to prevent injury to the delicate anatomic structures that can otherwise not be visualized." said Clark C. Chen, IVID, PhD, Lyle A. French Professor and Chair of Neurosurgery, University of Minnesota School of Medicine. "By performing the surgeries in the IVIRI suite, the surgeon can use the MRI to directly visualize the anatomy and perform the surgery through a small incision."

The ClearPoint system is the only available navigation platform that allows the neurosurgeon to operate under continuous intra-procedural IVIRI guidance. The entire procedure takes place in an MRI suite and eliminates the need to move the patient to and from an operating room and an MRI scanner. The direct visualization of events as they occur during surgery allows the neurosurgeon to adjust their maneuvers in real-time, thereby improving the safety of the procedure. This visualization was not previously possible.

"The patient that we treated today had previously undergone a conventional brain tumor surgery. It took him nearly a year to regain his ability speak and resume his daily activities." Said Chen. "When the tumor recurred, the patient was reticent to repeat this experience and refused conventional surgery. Fortunately, we were able to offer him a MRI-guided minimally invasive procedure."

Performing the procedure in an MRI suite, Dr. Chen used the ClearPoint device to precisely define and place a laser delivering probe into multiple regions of the tumor. The tumor cells were destroyed by laser-generated heat. The heat generation is monitored in real time through the use of the MRI as to prevent injury to the normal, healthy tissue. Chen commented "by combining the ClearPoint and the laser technology, I was able to safely treat a large tumor through an incision smaller than a pencil eraser.'

The patient fully recovered from the surgery and was discharged home the day after surgery.

"In stark contrast to the negative experience with his prior brain surgery, the patient was extremely pleased with the outcome of this surgery and expressed that he would have no reservations with future such surgeries should the need arise.' Said Chen.

"We are excited to add University of Minnesota, a leader in minimally invasive neurosurgery, to our growing installed base of ClearPoint users," commented Wendelin Maners, VP of Commercial Operations at MRI Interventions. "The transition to minimally invasive procedures in all other specialties in medicine has been done in concert with live-imaging that can guide these precise procedures. Our ClearPoint platform is designed specifically to help enable this transition to less invasive procedure for the patient and more efficient, less risky therapy delivery for the hospital."

University of Minnesota Neurosurgery

University of Minnesota Neurosurgery is an internationally leader in MRI-guided surgeries and had developed the first operative MRI suite in the U.S. Dr. Chen is a pioneer in minimally invasive endoscopic brain surgery, laser-based procedures, and gene therapy as treatment for malignant brain cancers such as glioblastoma.

About MRI Interventions,

Inc.Building on the imaging power of magnetic resonance imaging ("MRI"), MRI Interventions is creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain. The ClearPoint Neuro Navigation System, which has received 5 10(k) clearance and is CE marked, utilizes a hospital's existing diagnostic or intraoperative MRI suite to enable a range of minimally invasive procedures in the brain. For more information, please visit


The next generation of minimally invasive surgical procedures in the brain

ClearPoint Demonstration Video

Enabling the delivery of therapies to treat a range of neurological diseases and disorders

Our ClearPoint® system is used to perform minimally invasive surgical procedures in the brain guided by intraoperative MR imaging. Specifically, the ClearPoint system provides stereotactic guidance for the placement and operation of instruments or devices during the planning and operation of neurological procedures performed within the MRI suite using MR imaging.  ClearPoint procedures can be performed in a hospital’s existing MRI suite and can be used with both 1.5T and 3T scanners.  There are approximately 4,500 1.5T MRI scanners and 550 3T MRI scanners installed in hospitals throughout the United States.

Dr. Clark Chen to Lead U of M Medical School Department of Neurosurgery


Renowned neurosurgeon joins the University of Minnesota August 2017 MINNEAPOLIS/ST. PAUL (May 5, 2017)– The University of Minnesota Medical School is proud to announce Clark Chen, MD, Ph.D. as the Lyle French Chair in Neurosurgery and the Head of the University of Minnesota Medical School Department of Neurosurgery. "Dr. Chen is an innovative leader with a strong track record in research and clinical care," said Dr. Brooks Jackson, Dean of the Medical School and Vice President for the Health Sciences. “His leadership will be instrumental enhancing our strength in the neurosciences, and his oncology research will increase synergies between the neurosciences and the Masonic Cancer Center, University of Minnesota.” Chen is a nationally recognized brain tumor researcher and surgeon, with a dedicated interest in understanding how glioblastomas acquire resistance to radiation and chemotherapy. He is an NIH RO1 funded investigator with research focused on developing novel diagnostic and therapeutic approaches for brain tumor patients. He is also a leader in the study of DNA repair and gene therapy in brain tumors. "The University of Minnesota has a world-class scientific research and clinical community. It has a tremendous legacy in academic neurosurgery," said, Dr. Clark Chen. “I am excited and honored to take on a role that will allow me to build upon the excellent leadership and research of generations of neurosurgeons." Chen is currently the Chief of Stereotactic and Radiosurgery, Vice-Chairman of Neurosurgery and Professor of Neurosurgery at the University of California San Diego (UCSD). He played pivotal roles as the Principal Investigator of several surgery-based brain tumor trials, including studies using viruses engineered to destroy brain cancer cells. Clinically, he was at the forefront of developing and applying novel surgical tools, including the use of laser and ultrasound, as a treatment for brain tumor patients. Prior to his role at UCSD, he led the brain tumor programs at Beth Israel Deaconess Medical Center at Harvard Medical School and the Dana-Farber Cancer Institute. He has authored more than 200 peer-reviewed papers in the field of neuro-oncology, including publications in Nature, Nature Genetics, Science Translational Medicine, and the Proceedings of the National Academy of Sciences. “Dr. Chen’s research laboratory in the Masonic Cancer Research Building will co-locate him adjacent to other top oncology clinician researchers in neuroscience, comparative oncology, and pathology. I hope to see collaborations borne from this proximity bring new insights into glioblastoma research,” said Douglas Yee, MD, Director, Masonic Cancer Center, University of Minnesota. Dr. Chen is also the recipient of several highly competitive research awards including the Damon Runyon Fellowship Award, the Sidney Kimmel Scholar Award, the Burroughs Wellcome Foundation Career Award in Medical Sciences, the Sontag Foundation Distinguished Scientist Award, the Doris Duke Foundation Clinical Scientist Award, and the Forbeck Scholar Award. In 2015, Dr. Chen received the Presidential Award of Achievement from the President of Taiwan, Ma Ying-jeou. The award is given annually by the Taiwanese government to individuals of Taiwanese heritage who have made exceptional contributions to their profession. Chen says his work is motivated by his patients and his family. "I am the first in my family to have received a college education, and I remind myself constantly, that I am the son of two extraordinary people who have devoted themselves to my success. I also remind myself of the many brain tumor patients who the current standard of therapy fails” said Chen. “The reason I chose my profession is to keep the promise that I made to my mother – to study all the things that she never had a chance to.” Chen received his B.S. in biology from Stanford University, his M.S. in epidemiology from Columbia University, and his M.D. and Ph.D. degrees from Harvard Medical School. He subsequently completed his neurosurgery training at the Massachusetts General Hospital, including a clinical fellowship in radiosurgery and a second fellowship on stereotactic neurosurgery. Dr. Chen brings unique and valuable experience to the University of Minnesota,” said Jackson. “I am excited to bring a physician-scientist of his caliber on as a member of our leadership team.
Translate Me